ZytoGen offers

• On-site Next Generation Sequencing analysis in CAP-accredited laboratory for whole chromosome copy number imbalances

• Embryo analysis from single fresh or frozen cell

• 0% failure rate

• Board-certified High-Complexity Clinical Laboratory Director

• Ph.D. and Master’s Degree-level Molecular Technologists

• Responsive, 24-hour availability for patients and doctors

• Personalized, client-focused approach

• A normal embryo contains 23 pairs of chromosomes. 

• Aneuploid embryos have missing or extra chromosomes.
   

• The majority of pregnancies with aneuploid embryos result in miscarriage.

ZytoGen’s leaders have established a global reputation for their WORK in improving the success rate for In-Vitro Fertilization. Signature accomplishments include:

Next Generation Sequencing (NGS): 
Presentation of key research demonstrating the efficacy of NGS in PGS at the ESHRE conference in Munich, Germany in Summer 2014.

Time-Lapse Imaging: 
A 2014 study, published in BMC Medical Genomics, demonstrating the effectiveness of time-lapse incubation combined with aCGH screening over conventional incubation with traditional morphology in the selection of blastocysts for increased implantation rates.

Array Comparative Genomic Hybridization:
In 2012, ZytoGen’s co-founders provided the first direct evidence that PGS can increase the chances of a successful pregnancy.

Published in 2012 in Molecular Cytogenetics, this study was the result of the world’s first randomized clinical trial with 24Sure chromosome screening, and demonstrated the efficacy of PGS in increasing the rate of successful pregnancies following selective implantation of euploid embryos, even in younger patients with more favorable IVF outcomes.

The work of ZytoGen’s co-founders has been recognized by BBC News, the New York Times, and by key opinion leaders in the field of fertility and cytogenetics.

Click here for more information and downloads.